Search company, investor...

Kinetic River

Submit Your Analyst Briefing

Founded Year



Grant - III | Alive

Total Raised


Last Raised

$2.5M | 6 mos ago

About Kinetic River

Kinetic River is a biophotonics design and product development company specializing in flow cytometry. The company offers flow cytometry instrumentation solutions, including the Potomac modular flow cytometer and the Danube, a fluorescence lifetime flow cytometer. Kinetic River also provides a range of expert witness services, training seminars, and technical consulting services to clients worldwide.

Headquarters Location

897 Independence Avenue Suite 4A

Mountain View, California, 94043,

United States


Missing: Kinetic River's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kinetic River's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Kinetic River Patents

Kinetic River has filed 15 patents.

The 3 most popular patent topics include:

  • Cell biology
  • Flow cytometry
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics




Spectroscopy, Molecular biology, Microscopy, Mass spectrometry, Biotechnology


Application Date


Grant Date



Related Topics

Spectroscopy, Molecular biology, Microscopy, Mass spectrometry, Biotechnology



Latest Kinetic River News

08:32 EDT NIH Backs Kinetic River Approach to Autofluorescence-Free Flow Cytometry with Phase II SBIR Grant

Mar 23, 2022

News provided by Share this article Share this article Award also supports extension of advanced Time-Resolved technology for increased flow cytometry sensitivity and improved leukemia diagnostics MOUNTAIN VIEW, Calif., March 23, 2022 /PRNewswire/ -- Kinetic River Corp., a leader in advanced flow cytometry technologies, announced today it has been awarded a Phase II Small Business Innovation Research (SBIR) grant funded by the U.S. National Institutes of Health (NIH). The competitive $2.5-M grant was awarded by the National Institute of General Medical Sciences (NIGMS), which fosters development of innovative biomedical platforms. This is the fifth SBIR award received by Kinetic River to date and supports the company's industry-leading development of an autofluorescence-free flow cytometry platform for enhanced analytical sensitivity. Leukemia is a blood cancer that can take many forms. In Acute Myeloid Leukemia (AML), an aggressive and often fatal form, myeloid cells (purple) grow out of control, crowding out red blood cells (pink) and causing severe health problems such as anemia and bleeding disorders. The effort funded by the latest NIH award to Kinetic River is aimed in part at improving the characterization of samples from AML patients. Image credit: "Acute Promyelocytic Leukemia, Marrow Aspirate" by euthman, CC BY 2.0. Flow cytometry, the fluorescence-based high-speed identification and characterization of cells, is a ubiquitous technique with research and clinical applications ranging from oncology to immunology, cell biology, and infectious disease diagnostics. As with all analytical techniques, the sensitivity of flow cytometry is subject to limitations due to background noise in the measurement. One major source of background noise is "autofluorescence": fluorescence intrinsic to a cell that obscures the signal from the added fluorescent markers used to label cells in a sample, making it hard or impossible to characterize certain types of cells. Existing efforts by cytometrists to handle autofluorescence pose unsatisfactory tradeoffs, impairing sensitivity or making certain detection channels unusable altogether. The NIH-funded Phase I project Kinetic River completed in 2020 demonstrated the ability of its "Colorado" time-resolved technology to automatically remove autofluorescence background from cell measurements. This new award enables expansion of that effort into product development and commercialization. By performing fluorescence measurements in the time domain, the Colorado platform can distinguish autofluorescence background from the fluorescent signals of added cell markers, even when those emissions have completely overlapping spectra. This results in a radical increase of sensitivity of flow assays for certain cell types. Giacomo Vacca, Ph.D., president of Kinetic River, said, "We couldn't be happier with the incredible support of NIGMS and the NIH. Their continuing underwriting of research and development in biomedicine has allowed us to move aggressively from concept to engineering. Thanks to their multiple awards, our time-resolved flow cytometry technology platform is now solidly established, and with this grant we are shifting into the product and application development phase." Dr. Vacca added that biological validation of the Phase II effort will focus on improving the sensitivity of assays used to characterize samples from patients with Acute Myeloid Leukemia, a type of blood cancer. Several leaders in the field expressed support for the awarded project. Pratip K. Chattopadhyay, Ph.D., of Talon Biomarkers and a consultant on this project, commented, "Single-cell technology has evolved tremendously in the last 20 years, leading to dramatic steps forward in our understanding of biology and disease. Time-resolved flow cytometry is another step forward in this evolution, and is likely to offer real advantages over other platforms. Kinetic River is poised to demonstrate this quickly with their Phase II SBIR award." Christopher Bare, assistant professor at the Icahn School of Medicine at Mount Sinai, who is not involved with the project, said "Intrinsic cellular fluorescence fundamentally reduces the dynamic range of any currently available system when measuring any biological material." Prof. Bare added, "The Colorado technology really has the potential to reveal the invisible in our samples and dramatically improve cell classification methods. I'm pretty excited!" The time-resolved cell analysis technology developed at Kinetic River has applications beyond automated autofluorescence removal, including compensation-free flow cytometry (the subject of another NIH-funded Phase II SBIR project recently completed by Kinetic River) and highly multiparametric flow cytometry. About Kinetic River - Kinetic River Corp. designs and manufactures advanced flow cytometry systems. Based in California, Kinetic River offers cutting-edge instrumentation solutions for biomedical research, life sciences, and other fields, including the on-market Potomac modular flow cytometer and the Arno compensation-free flow cytometer (under development). For more information, visit Kinetic River® and the Kinetic River logo are registered trademarks of Kinetic River Corp.  Research reported in this release was supported by NIGMS of the National Institutes of Health under grant numbers R43GM131619 and R44GM131619. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Contact:

Kinetic River Frequently Asked Questions (FAQ)

  • When was Kinetic River founded?

    Kinetic River was founded in 2010.

  • Where is Kinetic River's headquarters?

    Kinetic River's headquarters is located at 897 Independence Avenue, Mountain View.

  • What is Kinetic River's latest funding round?

    Kinetic River's latest funding round is Grant - III.

  • How much did Kinetic River raise?

    Kinetic River raised a total of $2.5M.

  • Who are the investors of Kinetic River?

    Investors of Kinetic River include National Institutes of Health and National Institute of General Medical Sciences.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.